2024-09-10 21:38:22,389 - INFO - Extracted 10 link records.
2024-09-10 21:38:22,391 - INFO - Extracted 5 link records.
2024-09-10 21:38:22,394 - INFO - Extracted 8 link records.
2024-09-10 21:38:22,394 - INFO - Unique links to process: 10
2024-09-10 21:38:22,394 - INFO - Starting to process link: http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice
2024-09-10 21:38:24,360 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice, now generating post.
2024-09-10 21:38:25,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:28,429 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:28,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:28,809 - INFO - Image query: ‚Äúcancer treatment clinical trial‚Äù
2024-09-10 21:38:29,144 - INFO - Unique image link: https://images.pexels.com/photos/7659894/pexels-photo-7659894.jpeg
2024-09-10 21:38:29,145 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice
2024-09-10 21:38:29,145 - INFO - Starting to process link: http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/
2024-09-10 21:38:29,982 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/, now generating post.
2024-09-10 21:38:41,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:45,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:46,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:46,056 - INFO - Image query: "rubella vaccination and multiple sclerosis"
2024-09-10 21:38:46,333 - INFO - Unique image link: https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg
2024-09-10 21:38:46,333 - INFO - Post generated successfully for link: http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/
2024-09-10 21:38:46,333 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study
2024-09-10 21:38:48,468 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study, now generating post.
2024-09-10 21:38:53,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:57,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:57,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:38:57,433 - INFO - Image query: "digital biomarkers in Parkinson's disease"
2024-09-10 21:38:57,676 - INFO - Unique image link: https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg
2024-09-10 21:38:57,677 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study
2024-09-10 21:38:57,677 - INFO - Starting to process link: http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html
2024-09-10 21:38:59,289 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html, now generating post.
2024-09-10 21:39:13,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:39:16,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:39:17,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:39:17,154 - INFO - Image query: "Type 1 diabetes research and clinical trial"
2024-09-10 21:39:17,462 - INFO - Unique image link: https://images.pexels.com/photos/6823751/pexels-photo-6823751.jpeg
2024-09-10 21:39:17,462 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html
2024-09-10 21:39:17,462 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-10 21:39:48,059 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-10 21:39:50,506 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:39:50,507 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-10 21:39:50,507 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-10 21:39:50,507 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-10 21:39:50,507 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder
2024-09-10 21:39:52,742 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder, now generating post.
2024-09-10 21:39:59,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:02,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:02,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:02,745 - INFO - Image query: "VHL disease treatment"
2024-09-10 21:40:03,289 - INFO - Unique image link: https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg
2024-09-10 21:40:03,289 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder
2024-09-10 21:40:03,289 - INFO - Starting to process link: http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant
2024-09-10 21:40:05,563 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant, now generating post.
2024-09-10 21:40:08,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:11,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:11,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:11,744 - INFO - Image query: "neurosurgery technology"
2024-09-10 21:40:12,100 - INFO - Unique image link: https://images.pexels.com/photos/28158899/pexels-photo-28158899.jpeg
2024-09-10 21:40:12,100 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant
2024-09-10 21:40:12,100 - INFO - Starting to process link: http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/
2024-09-10 21:40:13,633 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/, now generating post.
2024-09-10 21:40:19,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:22,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:22,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:22,632 - INFO - Image query: mRNA vaccine research
2024-09-10 21:40:22,921 - INFO - Unique image link: https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg
2024-09-10 21:40:22,921 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/
2024-09-10 21:40:22,921 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-10 21:40:27,029 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-10 21:40:27,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:27,588 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-10 21:40:27,588 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-10 21:40:27,588 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-10 21:40:27,588 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial
2024-09-10 21:40:30,733 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial, now generating post.
2024-09-10 21:40:37,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:40,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:40,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 21:40:40,865 - INFO - Image query: "COPD treatment research"
2024-09-10 21:40:41,173 - INFO - Unique image link: https://images.pexels.com/photos/7578803/pexels-photo-7578803.jpeg
2024-09-10 21:40:41,173 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial
2024-09-10 21:40:41,173 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7659894/pexels-photo-7659894.jpeg'}
2024-09-10 21:40:41,173 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,173 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg'}
2024-09-10 21:40:41,173 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,173 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg'}
2024-09-10 21:40:41,173 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,173 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823751/pexels-photo-6823751.jpeg'}
2024-09-10 21:40:41,174 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,174 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg'}
2024-09-10 21:40:41,174 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,174 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/28158899/pexels-photo-28158899.jpeg'}
2024-09-10 21:40:41,174 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,174 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg'}
2024-09-10 21:40:41,174 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,174 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7578803/pexels-photo-7578803.jpeg'}
2024-09-10 21:40:41,174 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 21:40:41,174 - INFO - Sending 8 log entries to Firebase.
2024-09-10 21:40:43,952 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 8 posts added.', 'documentIDs': ['1bG3H5UqBdDUO5BirOz9', 'b0lNjsXLpyZj93znKaJE', 'X6fisepv94mxSLnWAqm7', 'nuA5EyynKAZWFdnzEYul', 'cjQ1XFPjaN4P6lTSafWm', 'eLFUY1WvoItQpWeY5XzA', 'ppNgLf2FcHJSx7gEpRTT', 'AIayfFa52LSEhOvtJmxm']}
2024-09-10 21:40:43,952 - INFO - Received 8 document IDs from Firebase.
2024-09-10 21:40:43,952 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:30:00', '2024-09-10 21:38:28', 'üîç Have you explored the potential of combining Atezolizumab and Bevacizumab in clinical practice? Recent insights drawn from the IMBrave150 trial provide an intriguing landscape for non-viral hepatocellular carcinoma treatment. \n\n- The IMBrave150 trial results highlighted a significant improvement in overall survival and progression-free survival among patients treated with the atezolizumab and bevacizumab combination compared to sorafenib alone. \n- In practice, clinicians report varied experiences, with many appreciating the positive outcomes and manageable safety profile associated with this dual therapy. \n- As these discussions unfold, it‚Äôs crucial to consider patient selection and the potential benefits versus risks of combination therapy in real-world settings. \n- ü§ù Engaging with peers on this topic may reveal further insights and help refine treatment approaches tailored to patient needs.\n\nAs we embrace newer regimens, how are you adapting your practice with the advent of combination therapies? \n\nFor deeper insights from key opinion leaders, check out the full article here: https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice', ['Life Sciences & BioTech', 'Oncology', 'HealthTech', 'ClinicalTrials', 'DigitalHealth'], 'https://images.pexels.com/photos/7659894/pexels-photo-7659894.jpeg', 'https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Using Atezolizumab + Bevacizumab in Practice\n============================================\n\nSeptember 9, 2024\n\nBy Daniel Ahn, DO  \nRahul Gosain, MD  \nRohit Gosain, MD\n\nKey opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.\n\n**Video content above is prompted by the following:**\n\n* What are your impressions on the data from the IMBrave150 trial?\n* Please share your experience with using atezo + bev in your practice.', 'gpt-4o-mini']
2024-09-10 21:40:43,954 - INFO - Logged data to databases/llm.csv with DocumentID: 1bG3H5UqBdDUO5BirOz9.
2024-09-10 21:40:43,954 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:20:00', '2024-09-10 21:38:45', 'ü§î Did you know that infection with the rubella virus may elevate the risk of developing multiple sclerosis (MS) in unvaccinated individuals? A recent Swedish study highlights this alarming association:  \n  \n- KEY FINDING: In unvaccinated individuals, the presence of antibodies against rubella is linked to a heightened risk of MS. The study suggests this could be due to a misdirected immune response triggered by the virus, echoing theories around "molecular mimicry."  \n  \n- üìä In the analyzed blood samples, nearly 93.7% of MS patients had anti-E1 antibodies, compared to 88.5% in healthy controls. More strikingly, unvaccinated MS patients were found to be FOUR TIMES MORE LIKELY to display rubella antibodies than their healthy counterparts.  \n  \n- In contrast, no significant difference in seropositivity was observed among vaccinated individuals, indicating vaccination may serve as a protective measure against this potential risk.  \n  \n- The researchers caution that while these findings are significant, further serological and epidemiological studies are essential to establish a clearer understanding of the relationship between rubella infection and MS development.  \n  \nAs healthcare providers, what role do you think vaccinations play in mitigating risks for conditions like MS? ü§∑\u200d‚ôÇÔ∏è  \nFor further reading, check out the full study here: https://onlinelibrary.wiley.com/doi/10.1111/ene.16387', ['Research & Clinical Trials', 'Neurology', 'InfectiousDiseases', 'HealthcareInnovation', 'ClinicalTrials', 'PatientSafety'], 'https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg', 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'MS risk in unvaccinated people may be elevated by rubella infection: Study\n=============== \n\nRubella infection may increase MS risk in unvaccinated people\n=============================================================\n\nFinding supports idea that certain infections may trigger MS immune response\n\nHaving antibodies against the rubella virus is associated with an increased risk of developing multiple sclerosis (MS) in unvaccinated people, a Swedish study suggests.\n\nThe findings show a rubella infection may be a risk factor for MS, reinforcing the hypothesis that certain viral infections may trigger the misleading immune response that drives MS.\n\n‚ÄúTo the best of our knowledge, this is the first report of an association between [rubella virus] and MS in pre-\xadMS samples,‚Äù wrote the researchers, who said additional studies will be needed to confirm the association between rubella infection and MS.\n\nThe study, ‚Äú[Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis](https://onlinelibrary.wiley.com/doi/10.1111/ene.16387),‚Äù was published in the _European Journal of Neurology._\n\n[MS is caused](https://multiplesclerosisnewstoday.com/risk-factors-for-multiple-sclerosis/) by an erroneous immune response that damages healthy parts of the brain and spinal cord. The reason for the immune response isn‚Äôt fully understood, but evidence suggests viral infections may be risk factors. Infection with the [Epstein-Barr virus](https://multiplesclerosisnewstoday.com/epstein-barr-virus-and-ms/) (EBV), in particular, is one of the strongest risk factors for the neurodegenerative condition and some studies have found an association between MS and the human herpesvirus-6A. Also, up to 78% of MS patients have antibodies against measles, varicella zoster, and rubella viruses in their spinal fluid.\n\nIt‚Äôs believed that, due to some similarities between viral and human molecules, the immune system may mistakenly attack nerve cells when trying to fight a viral infection. This ‚Äúmolecular mimicry‚Äù is one proposed mechanism that may explain the association between viruses and a greater risk of MS.\n\nThe rubella virus has several proteins that share similarities with human proteins. One protein from its envelope, called E2, is similar to myelin oligodendrocyte glycoprotein (MOG), an essential protein in myelin, the fatty coating that covers nerve cells and target of immune responses in MS.\n\nThese similarities raise the possibility of a connection between the rubella virus, the immune response against it, and developing MS.\n\nResearchers in Sweden compared blood samples from MS patients and controls collected before the neurological disease‚Äôs onset to determine if people who developed MS had signs of a previous rubella infection ‚Äî determined through the presence of anti-rubella antibodies ‚Äî before their diagnosis.\n\n‚ÄúWith samples from both the pre-\xadvaccination era and through the different stages of rubella vaccination in Sweden, we explored a unique opportunity to study [the rubella virus] in the field of MS,‚Äù the researchers wrote.\n\nThe study included blood samples from 670 MS patients and 670 matched controls. In both groups, female patients represented the majority (84%) and the median age was 25.\n\nThe researchers tested the samples for the presence of antibodies (seropositivity) that targeted the rubella E1 protein, which the virus uses to infect human cells, and their reactivity. More MS patients (93.7%) had anti-E1 antibodies than healthy controls (88.5%), data showed.\n\nWhen patients and controls were divided based on their rubella vaccination status, seropositivity was only significantly higher in MS patients than controls in unvaccinated people, in whom the presence of antibodies indicates a previous rubella infection. After adjusting for factors such as antibodies against other viruses and vitamin D levels, unvaccinated MS patients were four times more likely to have rubella antibodies than unvaccinated controls. No significant differences were observed in vaccinated patients after accounting for the same factors.\n\nThe presence of antibodies in ‚Äúunvaccinated subjects (i.e., representing rubella infection) was associated with a higher risk of developing MS,‚Äù the researchers wrote. ‚ÄúMolecular mimicry is an attractive hypothesis for a possible mechanism behind these findings.‚Äù\n\nThe researchers advised caution when interpreting their findings, mainly because the test they used to determine seropositivity can have a lot of false negatives. Also, most of the participants received the combined measles, mumps, and rubella vaccine, adding variables that weren‚Äôt evaluated in the study.\n\n‚ÄúFurther serological and epidemiological studies are needed to support our findings,‚Äù they wrote.', 'gpt-4o-mini']
2024-09-10 21:40:43,955 - INFO - Logged data to databases/llm.csv with DocumentID: b0lNjsXLpyZj93znKaJE.
2024-09-10 21:40:43,955 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:05:00', '2024-09-10 21:38:57', "üåü Have you considered the transformative potential of digital biomarkers in managing Parkinson's disease? \n\n- Regeneron has joined the innovative LEARNS trial led by Koneksa, a study harnessing smartphone and wearable technologies to track disease progression in Parkinson's patients. üì± \n- This research aims to establish reliable digital biomarkers that could reshape the development of disease-modifying therapies, a much-needed advancement in the field since current assessments often rely on subjective measures. \n- With up to 70 participants being monitored over a 12-month period, preliminary findings are anticipated next year. The integration of real-time data sharing could significantly enhance natural history analysis and clinical trial designs.  \n- Notably, other initiatives like the DREAM Challenge are also exploring ways to effectively utilize data from consumer wearables to track key symptoms such as muscle tremor and dyskinesia. \n\nAs we advance in this digital era, how do you see the role of technology evolving in the treatment and monitoring of neurodegenerative diseases? ü§î \n\nFor a deeper dive into the study, check it out here: https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study", ['HealthTech & Startups', 'DigitalHealth', 'Neurology', 'ClinicalTrials', 'PatientEngagement', 'HealthTech'], 'https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg', 'https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Regeneron joins Koneksa Parkinson\'s digital biomarker study\n\nRegeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with Parkinson\'s disease.\n\nThe LEARNS trial ‚Äì which started earlier this year ‚Äì is using smartphone and wearable technologies to monitor disease progression in Parkinson\'s patients and find ways to use digital biomarkers in the development of disease-modifying therapies.\n\nRegeneron has become a member of the data syndication programme for LEARNS, joining MSD/Merck & Co, which signed up in March, and will have real-time access to data and results from the study. Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.\n\nQuantitative tools for measuring progression are lacking in Parkinson\'s and other neurological disorders, with clinicians relying on subjective measures that make it harder to monitor patients, particularly as the rate of symptom decline fluctuates and varies wildly between individuals with the disease.\n\nLEARNS is set to enrol up to 70 participants with Parkinson\'s who will be followed for 12 months, with first results expected next year. It uses the Koneksa neuroscience toolkit, which combines iPhone-based active assessments and passive monitoring using a wrist-worn wearable.\n\n"Detecting the earliest signs of Parkinson\'s disease and establishing the necessary evidence of validity for new measures are critical needs within the healthcare community," said Chris Benko, Koneksa\'s chief executive.\n\n"Our goal is to bring together biotech and pharma companies with real-time data sharing and analysis to expedite the validation and adoption of digital measures to unlock more data insights in clinical trials," he added.\n\nOther projects looking at digital biomarkers for Parkinson\'s include the crowd-sourced DREAM Challenge, which saw 40 research teams from around the world contribute ways to process accelerometer and gyroscope data from consumer wearable devices that can be used to track muscle tremor, dyskinesia, and bradykinesia - three prominent symptoms of the disease.\n\nRegeneron\'s pipeline doesn\'t currently include a clinical-stage treatment for Parkinson\'s, but it is working on drugs for other neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS).\n\n"At Regeneron, we believe that digital biomarkers have the potential to improve the development of novel therapeutics, and collaboration helps make this a reality," said the company\'s head of clinical development for genetic diseases, Gary Herman.\n\n"Koneksa\'s data syndication community allows us to leverage collective expertise and gain insights that will inform future investigational therapies for Parkinson\'s disease."', 'gpt-4o-mini']
2024-09-10 21:40:43,956 - INFO - Logged data to databases/llm.csv with DocumentID: X6fisepv94mxSLnWAqm7.
2024-09-10 21:40:43,957 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 08:59:00', '2024-09-10 21:39:16', "üåü Exciting developments in the realm of Type 1 Diabetes care! \n\n- Diamyd Medical is pursuing an accelerated approval pathway for their innovative treatment, Diamyd¬Æ (rhGAD65/alum), designed to preserve endogenous insulin production in patients with Stage 3 Type 1 Diabetes.  \n\n- A recent positive futility analysis has invigorated their confidence in the treatment's ability to modify the disease, and results from an upcoming interim study are expected around March 2026. This interim readout will rely on key efficacy data from approximately 170 participants, pivotal for their Biologics License Application (BLA) to the FDA.  \n\n- With fast track designation already achieved, and the FDA's acknowledgment of C-peptide levels as a valid surrogate endpoint, Diamyd is on a path that reflects an increasing recognition of unmet medical needs. This expedited pathway allows promising therapies to reach patients faster.  \n\n- üöÄ The ongoing DIAGNODE-3 trial is actively recruiting, aiming for around 330 patients across the U.S. and Europe, with a focus on those carrying the HLA DR3-DQ2 genotype. This subgroup constitutes about 40% of Stage 3 Type 1 Diabetes patients, which enhances the significance of previous positive outcomes.\n\nAs healthcare professionals, how can we better integrate such precision medicine approaches into our diabetes management strategies? ü§î \n\nFor more information, check out the full release here: https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html", ['Life Sciences & BioTech', 'DigitalHealth', 'PrecisionMedicine', 'DigitalHealth', 'ClinicalTrials', 'Endocrinology'], 'https://images.pexels.com/photos/6823751/pexels-photo-6823751.jpeg', 'https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine\n\nSTOCKHOLM, Sept. 9, 2024 /PRNewswire/ -- Diamyd Medical will pursue an accelerated approval pathway in the U.S. for its antigen-specific immunotherapy, Diamyd¬Æ (rhGAD65/alum), aimed at preserving endogenous insulin production in patients with Stage 3 Type 1 Diabetes. An earlier interim study readout from the ongoing Phase 3 trial, DIAGNODE-3, is planned to serve as the basis for a Biologics License Application (BLA) under the accelerated approval pathway. Results from the interim readout are expected around March 2026.\n\n"We are committed to working at full speed with our partners and in close dialogue with the FDA to seize this unprecedented opportunity of making Diamyd¬Æ available to patients as quickly as possible," says Ulf Hannelius, CEO of Diamyd Medical. "The earlier readout from the DIAGNODE-3 trial represents a critical step in this process and our confidence in Diamyd¬Æ\'s disease-modifying benefits is boosted by the positive outcome of the recently announced futility analysis. We look forward to working closely with the FDA to ensure that all necessary regulatory requirements are met."\n\nDiamyd Medical recently announced Fast track designation in the U.S. for Diamyd¬Æ, and that the U.S. Food and Drug Administration (FDA) has acknowledged that accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels, a measure of endogenous insulin production, in response to Diamyd¬Æ administration. The FDA\'s Accelerated approval program allows drugs for serious conditions that fills an unmet medical need to be approved based on a surrogate endpoint. Using a surrogate endpoint allows the FDA the potential to approve these drugs faster.\n\nTo prepare the BLA under the FDA\'s Accelerated Approval Program, Diamyd Medical plans to conduct an interim study readout, including efficacy data from approximately 170 participants who have completed their 15-month assessment and safety data from additional individuals enrolled in the DIAGNODE-3 trial. The primary endpoint for this analysis will be C-peptide, a surrogate endpoint now recognized by the FDA as reasonably likely to predict clinical benefit. Following the interim readout, the DIAGNODE-3 trial will continue to follow all enrolled patients until the 24-month end-of-study assessment. To date, 148 patients have been randomized in DIAGNODE-3. The results of the interim study readout are expected around March 2026, the exact time depending on the final number of participants to be included in the readout, followed by submission of a BLA under the accelerated approval pathway.\n\nThe DIAGNODE-3 trial, which is being conducted in eight European countries and the United States, is expected to fully recruit approximately 330 patients by the end of 2025, and all patients are expected to be fully treated before the time the earlier readout is to be performed. The trial focuses on recently diagnosed patients with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype; a subgroup of approximately 40% of Stage 3 Type 1 Diabetes patients that has been shown to respond to Diamyd¬Æ in previous trials.\n\n**About Diamyd Medical**\n\nDiamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd¬Æ is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company\'s prospective European Phase IIb trial, where Diamyd¬Æ was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Ume√•, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd¬Æ. Diamyd Medical also develops the GABA-based investigational drug Remygen¬Æ as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.\n\nDiamyd Medical\'s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company\'s Certified Adviser.\n\n**For further information, please contact:  \n**Ulf Hannelius, President and CEO  \nPhone: +46 736 35 42 41  \nE-mail: ulf.hannelius@diamyd.com', 'gpt-4o-mini']
2024-09-10 21:40:43,957 - INFO - Logged data to databases/llm.csv with DocumentID: nuA5EyynKAZWFdnzEYul.
2024-09-10 21:40:43,958 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 08:44:00', '2024-09-10 21:40:02', "üåü Exciting news for patients with von Hippel-Lindau (VHL) disease! Following the Scottish Medicines Consortium's endorsement, NICE is set to finalize the recommendation for MSD‚Äôs Welireg (belzutifan) for NHS usage in England and Wales!\n\n- Welireg is now recognized as a treatment option for adults with VHL-associated renal cell carcinoma, brain and spinal cord tumours, and pancreatic neuroendocrine tumours, especially when conventional local treatments aren't viable. \n\n- Previously, patients primarily relied on invasive surgeries or radiotherapy, often facing multiple procedures throughout their lives. With Welireg, a new chapter in treatment options emerges for approximately 100 eligible adults in England. \n\n- The approval is conditional, allowing use while further efficacy data is gathered - a balanced approach to addressing clinical uncertainties previously identified by NICE. \n\n- Patient stories highlight the transformative potential of Welireg, bringing relief from debilitating symptoms such as chronic pain, balance issues, and even nausea.  \n\nCould this shift towards more targeted treatments change the landscape of care for rare genetic disorders? Let‚Äôs discuss the implications! üß¨ \n\nFor further details, check out the original announcement here: https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder", ['Healthcare & Policy', 'HealthPolicy', 'PatientSupport', 'ClinicalTrials'], 'https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg', 'https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'NICE clears NHS use of MSD\'s Welireg for genetic disorder\n\nPatients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD\'s Welireg via the NHS, nearly a year after their counterparts in Scotland.\n\nIn final draft guidance due to be finalised before the end of the month, Welireg (belzutifan) has been recommended as an option for treating adults with von Hippel-Lindau (VHL) disease, a rare and life-shortening disease that can lead to the development of benign and cancerous tumours and cysts.\n\nSpecifically, Welireg becomes an option for VHL-associated renal cell carcinoma (RCC), brain and spinal cord tumours (haemangioblastomas), or pancreatic neuroendocrine tumours (pNETs) when localised treatment like surgery isn\'t appropriate.\n\nUntil now, the only therapies available to patients with VHL have been invasive surgery or radiotherapy, with patients usually requiring multiple surgeries throughout their lives.\n\nThere are only about 600 adults in England living with the condition, and around 100 of them could be eligible for treatment with Welireg, with another 50 cases per year thereafter.\n\nThe decision comes after NICE withheld a recommendation for the drug last December, saying there were "uncertainties" in the clinical and economic evidence submitted for its appraisal. The SMC in Scotland backed NHS use of the drug in October 2023.\n\nThe new NICE recommendation is conditional, meaning that Welireg can be used while more evidence for its efficacy is collected, according to Helen Knight, director of medicines evaluation at NICE. It comes after NHS England reached a commercial access deal with the manufacturer.\n\nThe appraisal committee heard from patient experts who explained that some people with VHL have a wide variety of debilitating symptoms depending on where the tumours are growing in the body. These include pain, loss of balance and motor skills, loss of vision, breathlessness, coughing, headaches, confusion, severe nausea, and fatigue.\n\nGraham Lovitt, chair of patient advocacy group VHL UK/Ireland, said Welireg has "game-changing potential" and has shown extraordinary results for some patients in trials, including stabilisation of the tumours, reduction in growth, and ‚Äì in some cases ‚Äì the eradication of tumours altogether.\n\n"We are delighted by NICE\'s recommendation of belzutifan [‚Ä¶] a significant milestone in the fight against this rare disease," he added. "This decision brings hope to qualifying patients and their families, offering them an alternative treatment option, when others become too high risk."\n\nWelireg (belzutifan), an oral HIF-2 alpha inhibitor, has been approved by the UK drugs regulator the MHRA for VHL since May 2022. MSD acquired it as part of its $2.2 billion takeover of Peloton Therapeutics in 2019.\n\nDespite the rarity of VHL tumours, MSD has blockbuster aspirations for Welireg, and now has a second regulatory approval for the drug in relapsed or refractory advanced RCC, with clinical trials on the go in glioblastoma multiforme, a hard-to-treat form of brain cancer.', 'gpt-4o-mini']
2024-09-10 21:40:43,958 - INFO - Logged data to databases/llm.csv with DocumentID: cjQ1XFPjaN4P6lTSafWm.
2024-09-10 21:40:43,959 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 06:12:00', '2024-09-10 21:40:11', 'üß† Have you heard about the latest innovation in neurosurgical technology? Longeviti Neuro Solutions has just secured a U.S. patent for the ClearFit cranial implant, a game-changer in the field of neurosurgery.\n\n- This translucent prosthetic not only supports brain-computer interface capabilities but also integrates brain mapping and neurosonography for improved surgical outcomes.\n- ‚è±Ô∏è What sets the ClearFit implant apart is its ability to provide neurosurgeons with real-time, detailed anatomical imaging, which enhances precision during procedures.\n- Furthermore, the inclusion of neurosonography allows for continuous, noninvasive monitoring of brain activity, drastically improving patient care without the need for invasive measures.\n\nJesse Christopher, CEO of Longeviti, believes this advancement could significantly lower costs and time for brain monitoring globally. How do you think such innovations will shape the future of neurosurgical practices? ü§î  \n\nFor further information, check out the full announcement here: https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant', ['HealthTech & Startups', 'HealthTech', 'Neurology', 'MedicalDevices', 'Surgery'], 'https://images.pexels.com/photos/28158899/pexels-photo-28158899.jpeg', 'https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Longeviti Neuro Solutions secures US patent for neurosurgical cranial implant\n=============================================================================\n\nA Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.\n\nIn a press release, Longeviti Neuro Solutions said the ClearFit implant combines brain-computer interface capability, brain mapping and neurosonography, which permits direct communication between the brain and external devices, along with the ability for patients to interact with the technology, Longeviti said in the release.\n\nThe implant, when paired with brain-mapping capabilities, allows neurosurgeons to receive real-time, detailed anatomical images, enabling them to enhance their precision during neurological procedures. Further, the company said, integrating neurosonography within the cranial implant enables clinicians to continuously monitor brain activity during surgery in a noninvasive manner.\n\n‚ÄúThis technology represents a significant advancement in the field of neurosurgery,‚Äù Longeviti Neuro Solutions CEO Jesse Christopher said in the release. ‚ÄúTogether, Longeviti and its partners will advance neurosonography and neurosurgical patent care to significantly reduce the cost and time it takes to monitor brains anywhere in the world.‚Äù\n\n**Source:** Press Release', 'gpt-4o-mini']
2024-09-10 21:40:43,959 - INFO - Logged data to databases/llm.csv with DocumentID: eLFUY1WvoItQpWeY5XzA.
2024-09-10 21:40:43,960 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 06:06:00', '2024-09-10 21:40:22', "üß¨ Did you know that mRNA technology might revolutionize our fight against mpox? \n\n- A groundbreaking study compared Moderna's investigational mRNA mpox vaccine to the traditional Modified Vaccinia Ankara (MVA) vaccine in non-human primates, revealing significant advantages for the mRNA candidate. \n\n- üìâ Results showed a shorter disease duration by over 10 days for mRNA-vaccinated animals, alongside fewer lesions and a reduced viral load, suggesting it may be more effective at lowering transmission rates. \n\n- All vaccinated macaques survived the lethal mpox challenge, while five of the unvaccinated control group did not. This highlights the enhanced protective nature of the mRNA vaccine compared to the currently licensed MVA vaccine. \n\n- Beyond immediate protection, the mRNA vaccine also showed potential cross-immunity against other Orthopoxviruses, raising hopeful prospects for future viral threats. \n\nAs we navigate evolving viral landscapes, how can we leverage these findings to enhance our current vaccination strategies and prepare for potential outbreaks? ü§î \n\nFor more insights on the study, check it out here: https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/", ['Research & Clinical Trials', 'ClinicalTrials', 'InfectiousDiseases', 'HealthTech', 'VirtualCare'], 'https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg', 'https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'mRNA vaccine provides enhanced protection against mpox\n======================================================\n\nThe mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.\n\nA study, funded by Moderna, the National institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) compared an investigational mRNA mpox vaccine from Moderna to a currently licensed Modified Vaccinia Ankara (MVA) vaccine. The new mRNA vaccine candidate more effectively limits symptoms and disease duration in non-human primates infected with a lethal strain of mpox.\n\nAlec Freyn, virology researcher at Moderna and co-first author, stated: ‚ÄúThis study is the first in a nonhuman primate model where we compare an investigational mRNA mpox vaccine directly to the current standard of care.‚Äù He continued: ‚ÄúWhen we put those vaccines head-to-head in primates, we saw improved responses from the mRNA vaccine in terms of not just protection from survival but also fewer lesions, shorter duration of disease, and less viral shedding in the blood and respiratory tract.‚Äù\n\nOriginally designed to combat smallpox, MVA vaccines contained weakened whole viruses. Yet, this weakening means that they provide limited protection compared to other vaccines. The use of mRNA technology enables vaccines to be developed to only include parts of the virus that are most likely to induce a lasting, protective immune response without exposing the person to a whole infectious virus. The investigational mpox mRNA vaccine is composed of four viral antigens that are essential for the virus to attach and enter host cells.\n\nPrevious research has demonstrated that mRNA vaccines can prevent lethal mpox infections in nonhuman primates but their ability to lessen disease severity has not been tested. Therefore, to directly compare the investigational mRNA vaccine to MVA vaccines, the team vaccinated six macaques with each vaccine and then exposed them to a lethal strain of mpox virus eight weeks after their initial vaccine dose. Also, they exposed a control group of six unvaccinated animals to mpox. Then, after infection, the researchers monitored the macaque‚Äôs health for four weeks and collected blood samples to study their immune response.\n\nDisease severity\n----------------\n\nFive of the unvaccinated control animals did not survive, whereas all 12 vaccinated animals did, regardless of which vaccine was used. The mRNA-vaccinated animals lost less weight and had fewer lesions than MVA-vaccinated animals, despite both vaccines limiting disease severity compared to the control group.\n\nFurthermore, the mRNA vaccine shortened disease duration, measured by the number of days for which the animals showed lesions, by more than 10 days compared to the MVA vaccine. Lower viral loads were in the blood and throat swabs, indicating that it might be more effective at reducing transmission.\n\nJay Hooper, virologist at the United States Army Medical Research Institute for Infectious Diseases and senior author explained: ‚ÄúWith the mRNA technology, we‚Äôre able to produce a vaccine that gives quite potent responses with a very tolerable safety profile‚Ä¶We‚Äôve been trying to get a vaccine that will prevent spread like ACAM2000¬Æ but without the safety issues. This is showing that mRNA technology might be able to fill that niche.‚Äù\n\nImmune response\n---------------\n\nThe mRNA vaccine resulted in a higher number of antibodies and antibodies with more diverse immune functions. Different classes of antibodies that were associated with enhanced viral control and fewer lesions were identified.\n\nFurthermore, the vaccine demonstrated potential to induce cross-immunity to other Orthopoxviruses, whereas the MVA vaccine results in smaller immune responses that are not as strongly neutralising for more remotely related Orthopoxviruses. Serum from the macaques immunised with the mRNA vaccine ‚Äúneutralised not only mpox but also vaccinia, cowpox, rabbitpox, camelpox, and ectromelia virus,‚Äù Freyn said. ‚ÄúWe believe that this vaccine may protect from other Orthopoxvirus threats that may emerge in the future.‚Äù\n\nNow, Moderna‚Äôs mRNA-1769 vaccine is being assessed in a Phase I/II clinical trial (NCT05995275) to determine the safety, tolerability and immune response of a range of doses of mRNA-1769.\n\nThis study was published in Cell.', 'gpt-4o-mini']
2024-09-10 21:40:43,961 - INFO - Logged data to databases/llm.csv with DocumentID: ppNgLf2FcHJSx7gEpRTT.
2024-09-10 21:40:43,961 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 05:56:00', '2024-09-10 21:40:40', 'üå¨Ô∏è Have you considered the potential of Nucala in treating COPD? GSK\'s recent MATINEE trial results offer hopeful insights.\n\n- Nucala (mepolizumab), an IL-5 inhibitor originally for severe asthma, shows a statistically significant reduction in moderate/severe exacerbations in COPD patients when added to inhaled maintenance therapy. This poses a promising new avenue for treatment!\n- üìä The efficacy demonstrated is described as "clinically meaningful," especially considering previous mixed results from the METREX and METREO trials.\n- With the lung disease affecting over 300 million individuals globally, and up to 40% suffering from type 2 inflammation, this could represent a significant market opportunity for Nucala as a therapeutic option for COPD.\n- GSK aims to discuss these findings with regulators, targeting potential approval for COPD treatment in the US early next year.\n\nAs we see a renewal of focus on COPD treatment options after years of stagnation, how do you see the integration of biologics like Nucala changing standard care for these patients? ü§î\n\nFor more detailed insights, check the full update here: https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial', ['Life Sciences & BioTech', 'HealthTech', 'LifestyleMedicine', 'Pulmonology', 'ClinicalTrials'], 'https://images.pexels.com/photos/7578803/pexels-photo-7578803.jpeg', 'https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'GSK says Nucala hits the target in new COPD trial\n\nGSK\'s severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.\n\nThe headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically significant reduction in the annualised rate of moderate or severe exacerbations compared to placebo that GSK said was "clinically meaningful." In the study, Nucala was added to inhaled maintenance therapy for COPD.\n\nGSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO.\n\nMETREX involved patients with a range of eosinophil levels and showed a statistically significant improvement for Nucala versus placebo on exacerbation rates. However, in METREO ‚Äì which focused on patients with higher levels only ‚Äì the difference between the two arms was not significant.\n\nThe company decided to file for approval regardless, but the FDA declined to approve the new indication in 2018, following the advice of an advisory committee, which found that GSK had not proved efficacy. It seems MATINEE will allow GSK to try its luck again.\n\nThe size of the improvement over placebo ‚Äì which reportedly extended for up to two years in the trial ‚Äì won\'t be available until the study is presented at a future medical congress, but is strong enough to warrant discussions with regulators about extending the indications for Nucala, according to the pharma group. It has previously suggested approval for COPD could come in the US in the first half of next year.\n\nNucala has been approved to treat severe eosinophilic asthma for almost a decade, and in the interim has had its label extended to include chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.\n\nThe drug remains one of GSK\'s top products, with sales of ¬£856 million ($1.1 billion) in the first half of this year, up 15%. COPD could open up a massive new market for the drug, which still has several years of patent life left before it could face biosimilar competition.\n\nThe lung disease affects more than 300 million people globally, with up to 40% of patients exhibiting type 2 inflammation characterised by a raised blood eosinophil count, which would make them suitable for treatment with Nucala.\n\nElevated eosinophil levels are associated with more severe COPD and a higher rate of exacerbations, the sudden flare-ups in symptoms that signal the progression of the disease and can lead to hospitalisation.\n\nThe MATINEE data comes at a time when options for COPD are on the up, after a decade with no new therapies.\n\nIn July, the European Commission became the first regulator worldwide to approve Sanofi and Regeneron\'s big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly after Verona Pharma got the go-ahead from the US FDA for its PDE 3/4 inhibitor Ohtuvayre (ensifentrine).\n\nDupixent ‚Äì which is due for a verdict from the FDA as a COPD therapy later this month ‚Äì was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used in all patients regardless of eosinophil levels.', 'gpt-4o-mini']
2024-09-10 21:40:43,962 - INFO - Logged data to databases/llm.csv with DocumentID: AIayfFa52LSEhOvtJmxm.
